Inhibition of Francisella tularensis phagocytosis using a novel anti-LPS scFv antibody fragment.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
06 08 2019
Historique:
received: 15 10 2018
accepted: 25 07 2019
entrez: 8 8 2019
pubmed: 8 8 2019
medline: 28 10 2020
Statut: epublish

Résumé

Francisella tularensis (Ft), the causative agent of lethal tularemia, is classified as a category A biological warfare threat agent. While Ft infection is treatable by antibiotics, many failed antibiotic treatments were reported, highlighting the need for effective new treatments. It has been demonstrated that binding of antibody-coated bacteria to the Fc receptor located on phagocytic cells is a key process needed for efficient protection against Ft. Yet, Ft utilizes the same receptor to enter the phagocytic cells in order to escape the immune system. To address the question whether an anti-Ft LPS antibody lacking the ability to bind the Fc receptor may inhibit the entry of Ft into host cells, a soluble scFv (TL1-scFv) was constructed from an anti Ft-LPS antibody (TL1) that was isolated from an immune single-chain (scFv) phage-display library. Bacterial uptake was assessed upon infection of macrophages with Ft live attenuated strain (LVS) in the presence of either TL1 or TL1-scFv. While incubation of LVS in the presence of TL1 greatly enhanced bacterial uptake, LVS uptake was significantly inhibited in the presence of TL1-scFv. These results prompt further experiments probing the therapeutic efficacy of TL1-scFv, alone or in combination with antibiotic treatment.

Identifiants

pubmed: 31388083
doi: 10.1038/s41598-019-47931-w
pii: 10.1038/s41598-019-47931-w
pmc: PMC6684794
doi:

Substances chimiques

Antibodies, Bacterial 0
Bacterial Vaccines 0
Lipopolysaccharides 0
Single-Chain Antibodies 0
Vaccines, Attenuated 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11418

Références

Lett Appl Microbiol. 2015 May;60(5):409-13
pubmed: 25598285
PLoS One. 2011;6(9):e24654
pubmed: 21931798
Mol Microbiol. 1996 May;20(4):867-74
pubmed: 8793882
Infect Immun. 2005 Sep;73(9):5892-902
pubmed: 16113308
Toxins (Basel). 2016 Mar 03;8(3):
pubmed: 26950154
Front Cell Infect Microbiol. 2017 Apr 11;7:122
pubmed: 28443249
PLoS One. 2014 Dec 23;9(12):e114622
pubmed: 25536105
Vaccine. 2014 Sep 8;32(40):5212-20
pubmed: 25068496
JAMA. 2001 Jun 6;285(21):2763-73
pubmed: 11386933
Vaccine. 2017 Dec 15;35(50):7001-7009
pubmed: 29102170
Appl Environ Microbiol. 2011 Mar;77(5):1608-18
pubmed: 21193666
PLoS One. 2018 Oct 22;13(10):e0205928
pubmed: 30346998
Infect Immun. 2011 Jun;79(6):2204-14
pubmed: 21422184
Medicine (Baltimore). 1985 Jul;64(4):251-69
pubmed: 3892222
Anal Biochem. 2016 Aug 1;506:22-7
pubmed: 27156814
Plasmid. 2010 Nov;64(3):156-61
pubmed: 20620161
Infect Immun. 2011 Apr;79(4):1770-8
pubmed: 21282410
MAbs. 2016;8(1):113-9
pubmed: 26496429
Infect Immun. 2015 Jan;83(1):77-89
pubmed: 25312957
Hybridoma (Larchmt). 2011 Feb;30(1):19-28
pubmed: 21466282
Anal Chem. 2014 Oct 7;86(19):9394-8
pubmed: 25215633
Vaccine. 2008 Mar 25;26(14):1773-85
pubmed: 18308432
Toxins (Basel). 2018 Feb 13;10(2):
pubmed: 29438273
Infect Immun. 2014 May;82(5):2098-105
pubmed: 24614653
Scand J Infect Dis. 2013 Sep;45(9):725-7
pubmed: 23746340
Antimicrob Agents Chemother. 2012 Oct;56(10):5406-8
pubmed: 22850512
Biosens Bioelectron. 2015 Feb 15;64:69-73
pubmed: 25194798
Vaccine. 2001 Aug 14;19(31):4465-72
pubmed: 11483272
Pathog Dis. 2016 Oct;74(7):
pubmed: 27511964
Infect Immun. 2006 Sep;74(9):5114-25
pubmed: 16926403
Immunol Rev. 2008 Oct;225:244-55
pubmed: 18837786
Front Microbiol. 2010 Nov 19;1:129
pubmed: 21687776
Mol Microbiol. 2012 Nov;86(3):611-27
pubmed: 22966934
Infect Immun. 2004 Sep;72(9):5340-8
pubmed: 15322031
Front Cell Infect Microbiol. 2014 Mar 28;4:40
pubmed: 24734221
Front Cell Infect Microbiol. 2017 Oct 16;7:446
pubmed: 29085810
J Inflamm Res. 2016 Nov 16;9:209-219
pubmed: 27895507
Clin Vaccine Immunol. 2009 Mar;16(3):414-22
pubmed: 19176692
J Leukoc Biol. 2016 Dec;100(6):1335-1347
pubmed: 27365531
J Immunol. 2007 Jul 1;179(1):532-9
pubmed: 17579074
Cell Microbiol. 2006 Aug;8(8):1361-70
pubmed: 16882038
Nat Rev Microbiol. 2004 Dec;2(12):967-78
pubmed: 15550942
Infect Immun. 2007 Jan;75(1):536-41
pubmed: 17030571
Clin Infect Dis. 2001 Aug 15;33(4):573-6
pubmed: 11462198
PLoS One. 2009 Jul 24;4(7):e6351
pubmed: 19629185
Curr Microbiol. 2017 Apr;74(4):499-507
pubmed: 28233060

Auteurs

Adva Mechaly (A)

The Department of Infectious Diseases, Israel Institute for Biological Research, Ness-Ziona, Israel.

Uri Elia (U)

The Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona, Israel.

Ron Alcalay (R)

The Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona, Israel.

Hila Cohen (H)

The Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona, Israel.

Eyal Epstein (E)

The Department of Biotechnology, Israel Institute for Biological Research, Ness-Ziona, Israel.

Ofer Cohen (O)

The Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona, Israel. oferc@iibr.gov.il.

Ohad Mazor (O)

The Department of Infectious Diseases, Israel Institute for Biological Research, Ness-Ziona, Israel. ohadm@iibr.gov.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH